Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 2,373 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Visual Function Clear all
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing

NCT07470463
View directory record Official record
Conditions
Differential Diagnosis, Diagnostic Accuracy
Interventions
AI Diagnostic System (AIMD.1)
Diagnostic Test
Lead sponsor
Magic Health Inc. (d.b.a. Nolla Health)
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

NCT00570843
View directory record Official record
Conditions
Comfort, Vision and Wear Time
Interventions
New PEG based artificial tear, Optive
Drug
Lead sponsor
Bp Consulting, Inc
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional

Evaluation of the Distortion Correction Data Collection (DCDC) App Software

NCT02337647
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
DCDC App
Other
Lead sponsor
University of Nebraska
Other
Eligibility
55 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Study of Safety and Performance of a Novel Ocular Lubricant in Subjects With Dry Eye Disease

NCT06444516
View directory record Official record
Conditions
Dry Eye Disease
Interventions
FID123300 ocular lubricant
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
9
States / cities
Maitland, Florida • Orlando, Florida • Franklin Park, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

AR-12286 in Combination With Latanoprost

NCT01302249
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
15
States / cities
New Haven, Connecticut • Roswell, Georgia • Shawnee Mission, Kansas + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Central Corneal Thickness On IOP Using Various Tonometers

NCT00570791
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Tonometer
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
166 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 4 Interventional

Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer

NCT06952660
View directory record Official record
Conditions
Cervical Cancer
Interventions
TIVDAK
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
131
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tempe, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of a Daily Wear Frequent Replacement Silicone Hydrogel Lens

NCT03920280
View directory record Official record
Conditions
Refractive Errors
Interventions
LID015385 contact lenses, Comfilcon A soft contact lenses, CLEAR CARE
Device
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
8
States / cities
Maitland, Florida • Orlando, Florida • Pensacola, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational

Social Worker in an Eye-Care Service

NCT03304535
View directory record Official record
Conditions
Glaucoma
Interventions
Not listed
Lead sponsor
Wills Eye
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Access Through Remote Eyesight (CARE) Study

NCT04926974
View directory record Official record
Conditions
Low Vision
Interventions
Low Vision Rehabilitation
Behavioral
Lead sponsor
New England College of Optometry
Other
Eligibility
55 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Active, not recruiting No phase listed Observational

Impact of Glaucoma and Visual Field Loss on Life Space

NCT03673644
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Questionnaires
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

NCT05411198
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
XEN45 (Glaucoma Gel Stent)
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 1Phase 2 Interventional

Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension

NCT00846989
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
RKI983A, Latanoprost
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
29
States / cities
Artesia, California • Inglewood, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 22, 2026, 4:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Attention and Visual Perception

NCT00111293
View directory record Official record
Conditions
Focal Lesions, Focal Brain Lesion
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 4:50 AM EDT
Not listed No phase listed Observational

Quality of Life and Visual Function in Uveitis Patients

NCT00407316
View directory record Official record
Conditions
Anterior Uveitis, Posterior Uveitis, Panuveitis, Uveitis
Interventions
Not listed
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
18 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2006 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age

NCT01365884
View directory record Official record
Conditions
Refractive Error
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
7 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

P200TE and Predicate Agreement and Precision Study

NCT05624593
View directory record Official record
Conditions
Normal, Retina Disease, Glaucoma
Interventions
P200TE, Predicate
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2022 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

NCT07495852
View directory record Official record
Conditions
Glaucoma
Interventions
Gen 2 Travoprost Intracameral Implant, Timolol eye drops 0.5%, Sham Procedure, placebo eye drops
Drug · Procedure · Other
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dothan, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting No phase listed Observational

Modifiable Variables in Parkinsonism (MVP)

NCT02194816
View directory record Official record
Conditions
Parkinson's Disease, Parkinsonism, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, Shy-Drager Syndrome, Corticobasal Degeneration, Dementia With Lewy Bodies, Pick Disease, Olivopontocerebellar Atrophies
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
19 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 4:50 AM EDT
Completed Phase 1 Interventional

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 4 Interventional

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

NCT07588152
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT)
Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 22, 2026, 4:50 AM EDT
Terminated Phase 4 Interventional

A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.

NCT03101501
View directory record Official record
Conditions
Presbyopia
Interventions
Mitomycin c, Raindrop Near Vision Inlay
Drug · Device
Lead sponsor
Key-Whitman Eye Center
Other
Eligibility
41 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Bloomington, Minnesota • Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 22, 2026, 4:50 AM EDT
Recruiting Phase 3 Interventional

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

NCT04782258
View directory record Official record
Conditions
Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions
Tolvaptan Suspension, Tolvaptan Tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
28 Days to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 22, 2026, 4:50 AM EDT